Presbyopia is a universal condition of the aging eye. With a wave of newly approved drops entering the market, there is a renewed interest in minimally invasive approaches to spectacle independence. Hyperopic presbyopes face a compounded burden, as near challenges begin earlier and adaptation curves are steeper.
Optimal Keratoplasty (Opti-K) is a noninvasive, office-based laser thermal keratoplasty designed to reshape the anterior stroma and create a multifocal cornea, temporarily improving presbyopia and hyperopia, with retreatment available as effects regress. It has received CE Mark in Europe as of 2012,1 recently obtained a Health Canada Class II medical device license,2,3 and is currently being evaluated under an Investigational Device Exemption for a phase 3 presbyopia trial.1,4
Here we describe immediate and 1-week outcomes in three community-referred hyperopic presbyopes treated during a manufacturer-sponsored Opti-K demonstration day.
What is Opti‑K?
Unlike ablative refractive procedures, Opti-K leaves the epithelium intact, requires no incision, and can be performed in a standard examination lane—making it one of the few presbyopia interventions that could realistically integrate into a community eyecare setting. Opti-K uses a 1.93 µm thulium laser delivered through a sapphire applanation window suction ring (SAWSR) to target 16 spots in the mid-peripheral anterior stroma.
The SAWSR provides a cooling effect to allow thermal compaction of the anterior stroma while protecting the epithelium from thermal injury.5 This results in a series of alternating steeper and flatter sectors that improves uncorrected near vision in presbyopes and uncorrected distance vision in hyperopes.6
This has been described as a “multifocal corneal profile” in the literature,6 and while no published data measuring the optical parameters exists—e.g., using optical bench testing as is done for IOLs—it is a reasonable inference judging by the improved uncorrected near VA without significant loss in distance VA in the emerging literature described below.
Figure 1: Opti-K device set up on a mobile platform. The patient lies on a bed beside the platform such that the arm assembly can rotate over their head. The SAWSR is placed similar to a gonioscopy lens and suction is applied via the vacuum pump. The surgeon can view the cornea for centration through the iPad.
The laser treatment is applied through the Fiber Distribution Hub (FDH) duct tube inserted through the SAWSR by depressing the foot pedal. The corneal curvature flattens in the midperiphery along the meridians treated to create multifocality.
Figure 1: Courtesy of VIS, Inc.
Emerging evidence on Opti-K
In one prospective trial in Italy (n=40) in low to moderate hyperopic presbyopes and emmetropic presbyopes, binocular uncorrected near visual acuity (UCNVA) improved from 20/62 Snellen equivalent to 20/28 within 1 hour of treatment, regressing to 20/39 by month 6. A second treatment within the first 45 days was performed in 16 eyes from 8 patients with similar functional improvement.6
Binocular uncorrected distance visual acuity (UCDVA) was also improved in hyperopic presbyopes from 20/38 to 20/23, regressing to 20/27 by month 6. In emmetropic presbyopes, UCDVA was 20/20 pretreatment and was preserved throughout follow up. No significant adverse events were reported.6
A recent preprint (not yet peer-reviewed) describes a retrospective observational cohort study of 145 eyes from 75 emmetropic presbyopes treated in the Bahamas. Of these, 66, 16, and 4 eyes received secondary, ternary, and quaternary treatments and 2 eyes of one patient received 10 treatments over a 5-year period.7 After primary Opti-K treatment, binocular UCNVA improved from 20/46 to 20/21 regressing to 20/29 at month 6 and 20/32 at month 24 with no change to UCDVA.
Similar patterns were observed after secondary treatments. Importantly, no clinically significant adverse events were reported in single or multiple treatment courses over the 24-month observation period, though follow-up retention declined over time (145 eyes to 60 and 23 at month 6 and 24 respectively), limiting longer-term conclusions.7 In both datasets, monocular UCNVA improved early and then regressed over time, whereas UCDVA was preserved (emmetropic cohort) or showed durable improvement (hyperopic cohort).
Peer-reviewed evidence for Opti-K remains limited to date. Beyond the two clinical studies described above, the procedure has been presented at major refractive surgery meetings including ASCRS,8,9 ESCRS,9 and ISRS10 since 2010, and described in a review article,11 and in the trade literature.1,12,13
Larger, independently conducted prospective trials are needed to establish the durability and reproducibility of these results—but the early signal is encouraging.
Surgical pearls from Dr. Maryam Taheri-Shirazi:
- During the procedure, careful attention should be paid to the amount of UCDVA improvement to determine the appropriate energy level for treatment.
- Centration is an important factor in preventing unwanted corneal aberrations, as this procedure makes the cornea multifocal and may cause corneal irregularities.
- The use of distilled water is another important consideration to help minimize unwanted corneal abrasion during the procedure.
Optimal keratoplasty clinical vignettes
As part of an Opti-K demonstration day, patients were referred by community eyecare professionals (ECPs) and vetted for treatment suitability by the staff physician provided by VIS Inc., the parent company for Opti-K. Refraction and functional testing were performed by the authors and trained technicians; imaging was interpreted by the authors.
Due to the real-world conditions of data collection during a demonstration event, some data points are missing and post-treatment care and data collection were managed by the referring ECPs under routine clinical conditions. Below are 3 clinical vignettes with the most complete data collection.
Clinical vignette 1: Low hyperopic presbyope
Clinical vignette 1 was a 57-year-old woman with low hyperopic presbyopia with unremarkable ocular health confirmed on slit lamp exam, OCT ONH/MAC, and Optos. Her refraction was consistent with the emmetropic to moderate hyperopic range studied in the Italian trial.
Immediately after the treatment, her binocular UCNVA improved to 20/20 and she reported notably improved near performance. She expressed immediate satisfaction and encouraged her husband (case 2) to proceed. At post-op day 5, binocular UCNVA had regressed to 20/30 (20/40-2 OD and 20/50 OS) though UCDVA remained 20/20. An increase in vertical coma was observed in both eyes, which appear to be consistent with the induced multifocal corneal profile.
Table 1: Clinical vignette 1- Pre- and post-operative visual function.
| PRE-OP | OD | OS |
|---|
| UCDVA | 20/30-2 | 20/30-1 |
| UCNVA | 20/70 | 20/70 |
| Autorefraction | +1.00-0.25x170 | +1.00DS |
| ARDVA | 20/20 | 20/20 |
| Manifest Refraction | +1.00-0.25x175 | +1.25DS |
| BCDVA | 20/20 | 20/20 |
| POST-OP 1 HOUR | | |
| UCDVA | 20/20 | 20/20-1 |
| UCNVA | 20/20 | 20/30 |
| Autorefraction | -0.50-0.75x032 | -0.25-0.25x169 |
| ARDVA | N/A | N/A |
| Manifest Refraction | Plano Sph | Plano Sph |
| BCDVA | N/A | N/A |
| POST-OP 5 DAYS | | |
| UCDVA | 20/20-1 | 20/20 |
| UCNVA | 20/40-2 | 20/50 |
| Autorefraction | +0.50-0.50x014 | +0.50-0.25x009 |
| ARDVA | N/A | N/A |
| Manifest Refraction | +0.50-0.25x030 | Plano Sph |
| BCDVA | 20/20 | 20/20 |
Figure 2: Corneal topography of clinical vignette 1 OD pre-treatment: Sim K 43.58/42.73 D, with 0.85 D of regular astigmatism.
Figure 2: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 3: Corneal topography of Case 1 OD 1-hour post-treatment: Ks 45.38/44.78 D (~1.7 D vs. pre), with mid-peripheral ring of steepening consistent with the 16-spot treatment geometry. The Placido rings show some mid-peripheral distortion.
Figure 3: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 4: Corneal topography of Case 1 OD Day-5 post-treatment: Ks partially regressed to 44.00/43.46 D, remaining above baseline (~0.4 D vs. pre), consistent with partial early regression of the thermal effect. There is an increase in the vertical coma as well.
Figure 4: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 5: Corneal topography of Case 1 OS pre-treatment: Sim K 43.73/42.99 D, with 0.75 D of regular astigmatism.
Figure 5: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 6: Corneal topography of Case 1 OS 1-hour post-treatment: Ks 45.38/44.78 D (~1.7 D vs. pre), with mid-peripheral ring of steepening consistent with the 16-spot treatment geometry. The Placido rings show some mid-peripheral distortion.
Figure 6: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 7: Corneal topography of Case 1 OS Day-5 post-treatment: Ks partially regressed to 44.00/43.46 D, remaining above baseline (~0.4 D vs. pre), consistent with partial early regression of the thermal effect. There is an increase in the vertical coma as well.
Figure 7: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Clinical vignette 2: Moderate hyperopic presbyope
Clinical vignette 2 was a 64-year-old man with moderate hyperopic presbyopia with unremarkable ocular health confirmed on slit lamp exam, OCT ONH/MAC, and Optos. Immediately after the treatment, he achieved UCNVA 20/20 OU and no longer required his spectacles. Similar to clinical vignette 1, some regression was noted by day 5. He nonetheless retained meaningful improvement from baseline, with UCDVA 20/30 OU and UCNVA 20/30 OU (20/50 monocularly).
As with Clinical vignette 1, higher-order aberration changes were noted with an increase in horizontal trefoil OD and vertical coma OS. Further, OD continued to steepen at day 5 though the clinical significance of a single observation is unclear.
Table 2: Clinical vignette 2 Pre- and post-operative visual function.
| PRE-OP | OD | OS |
|---|
| UCDVA | 20/120 | 20/60-1 |
| UCNVA | 20/200 | 20/100 |
| Autorefraction | +2.50-0.25x053 | +2.75-1.00x096 |
| ARDVA | N/A | N/A |
| Manifest Refraction | +2.25-0.25x048 | +2.25-0.75x100 |
| BCDVA | 20/20-1 | 20/20 |
| POST-OP 1 HOUR | | |
| UCDVA | 20/25-1 | 20/20-1 |
| UCNVA | 20/20-2 | 20/30 |
| Autorefraction | +0.50-0.25x037 | +0.75-1.25x090 |
| ARDVA | N/A | N/A |
| Manifest Refraction | Plano Sph | Plano Sph |
| BCDVA | N/A | N/A |
| POST-OP 5 DAYS | | |
| UCDVA | 20/30-1 | 20/30-1 |
| UCNVA | 20/50 | 20/50 |
| Autorefraction | +1.75-0.25x014 | +1.75-1.00x093 |
| ARDVA | N/A | N/A |
| Manifest Refraction | +1.75-0.25x055 | +1.50-1.00x105 |
| BCDVA | 20/20 | 20/20 |
Figure 8: Clinical vignette 2 OD immediately post-treatment.This image shows 16 mid-peripheral whitened foci corresponding to anterior stromal thermal treatment. These anterior stromal changes are transient and the Italian trial observed a correlating hyperreflective band on AS-OCT which had a median resolution time of approximately 5.4 months.6
Figure 8: Courtesy of Junaid Qureshi, OD.
Figure 9: Corneal topography of Case 2 OD pre-treatment: Sim K 40.00/39.51 D, with 0.49 D astigmatism—a flatter corneal profile than Case 1 consistent with higher hyperopia.
Figure 9: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 10: Corneal topography of Case 2 OD 1-hour post-treatment: Ks increased to 41.37/40.43 D (~1.1 D vs. pre), with mid-peripheral ring of steepening consistent with the 16-spot treatment geometry. The placido rings show some mid-peripheral distortion.
Figure 10: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 11: Corneal topography of Case 2 OD Day-5 post-treatment: Ks further increased to 42.49/42.01 D (~2.5 D vs. pre), with a mid-peripheral steepening still evident. There is a large increase in horizontal trefoil.
Figure 11: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 12: Corneal topography of Case 2 OS pre-treatment: Sim K 39.96/39.64 D, with 0.31 D astigmatism.
Figure 12: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 13: Corneal topography of clinical vignette 2 OS 1-hour post-treatment: Ks increased to 42.03/41.30 D (~1.8 D vs. pre), with mid-peripheral ring of steepening consistent with the 16-spot treatment geometry.
Figure 13: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 14: Corneal topography of clinical vignette 2 OS Day-5 post-treatment: Ks regressed to 40.79/40.28 D (~0.7 D vs. pre), with a mid-peripheral steepening still evident. There is a small decrease in oblique trefoil and a larger increase in vertical coma.
Figure 14: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Clinical vignette 3: Post-LASIK high hyperope
Clinical vignette 3 was a 58-year-old woman who was originally myopic with an Rx of -1.00-1.25x014 and -0.50-1.75x163. She was treated with
LASIK 20 years ago with subsequent regression to moderately high hyperopia. She has otherwise unremarkable ocular health confirmed on slit lamp exam, OCT ONH/MAC, and Optos.
This patient sits beyond the refractive range used in the only published Opti-K trial to date and as a post-LASIK patient, she may have altered corneal biomechanics compared to treatment-naive corneas. While her distance and near UCVA improved, the magnitude of change was insufficient for meaningful spectacle independence in daily activities.
She reported monocular ghosting at 1 hour post-op under uncorrected, best-corrected, and habitual-corrected conditions. These symptoms resolved by the end of day and she reported satisfactory vision with no concerns at a 1-month telephone follow-up with updated spectacle correction.
Table 3: Clinical vignette 3 Pre- and post-operative visual function. Monocular ghosting was reported post-treatment, but resolved by end of day.
| PRE-OP | OD | OS |
|---|
| UCDVA | 20/120 | 20/200 |
| Habitually corrected DVA | 20/30+1 | 20/30+1 |
| UCNVA | 20/400 | 20/400 |
| Autorefraction | +3.75-0.75x028 | +3.75DS |
| ARDVA | 20/30-1 | 20/30-2 |
| Manifest Refraction | +3.00-0.50x020 | +3.00DS |
| BCDVA | 20/20 | 20/20 |
| POST-OP 1 HOUR | | |
| UCDVA | 20/60 (monocular ghosting) | 20/70 (monocular ghosting) |
| Habitually corrected DVA | 20/20 (slow, monocular ghosting) | 20/20 (slow, monocular ghosting) |
| UCNVA | 20/50 | 20/50 |
| Autorefraction | +1.75-1.25x076 | +2.75-1.00x174 |
| ARDVA | 20/60 | 20/30+2 |
| Manifest Refraction | +2.25-0.50x030 | +2.75DS |
| BCDVA | 20/20-1 | 20/20-1 |
| POST-OP 5 DAYS | | |
| UCDVA | N/A | N/A |
| UCNVA | N/A | N/A |
| Autorefraction | N/A | N/A |
| ARDVA | N/A | N/A |
| Manifest Refraction | +3.00-0.50x045 | +3.00-0.25x040 |
| BCDVA | 20/20 | 20/20 |
Figure 15: Corneal topography of Case 3 OD pre-treatment: Sim K 43.14/41.84 D, with 1.29 D astigmatism, higher corneal cyl than Cases 1 and 2.
Figure 15: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 16: Corneal topography of Case 3 OD 1-hour post-treatment: Ks increased to 43.98/42.22D (~0.5 D vs. pre), with mid-peripheral ring of steepening consistent with the 16-spot treatment geometry.
Figure 16: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 17: Corneal topography of Case 3 OS pre-treatment: Sim K 43.37/42.25 D, with 1.13 D astigmatism, higher corneal cyl than Cases 1 and 2.
Figure 17: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
Figure 18: Corneal topography of Case 3 OS 1-hour post-treatment: Ks increased to 45.63/44.42 D (~2.2 D vs. pre), with mid-peripheral ring of steepening consistent with the 16-spot treatment geometry.
Figure 18: Courtesy of Ken Wan, OD, FAAO, Dipl ABO and Maryam Taheri-Shirazi, MD, FRCSC.
VIS-associated anecdotes
As part of the demonstration day, a senior VIS executive had his eyes retreated as well. He was a former hyperopic presbyope who has had 4 prior treatments over 16 years and presented with UCDVA 20/20 OD and OS and UCNVA 20/40 and 20/50. Pelli Robson contrast sensitivity pre-op was 1.75 and 1.70. This is within the normal range for an individual in his late 70s, consistent with preserved contrast sensitivity despite multiple retreatments.
At 1 hour post-operatively, he had some fluctuating visual acuity likely associated with ocular surface disease exacerbated by drops and suction. He reports this as consistent with his prior treatment experiences and resolving within a day.
His daughter-in-law, a +3.00 D hyperopic early presbyope, achieved immediate 20/20 distance and functional near sufficient for spectacle independence outside of fine print but had to depart before formal post-treatment refraction/VA testing. Both of these individuals were included as anecdotal context only, due to manufacturer ties and incomplete data.
Clinical observations from the clinical vignettes
- Clinical vignettes 1 and 2 (low to moderate hyperopic presbyopes with no prior corneal surgery) showed immediate functional improvement consistent with the published trial populations,6,7 with mild regression by day 5 and preserved gains over baseline.
- Clinical vignette 3 suggests that patients outside this refractive range or with prior corneal surgery may respond less predictably to a single treatment. Notably, despite suboptimal treatment response, the safety profile appeared favorable as symptoms resolved quickly and the patient was satisfied with updated spectacle correction at 1 month.
- Published data report treatment effects persisting 6 to 24 months following single and repeat treatments,6,7 and retreatment has been reported as safe, including in a small subset receiving three or more treatments.7
- Careful patient selection and conservative counseling are warranted until larger, longer-term independent series are available.
Disclosures and limitations
- Disclosure: Dr. Wan serves on the VIS Opti-K Canadian advisory board, unpaid, no equity.
- Small, non-consecutive series with limited follow-up and heterogeneous data collection intended as illustrative case vignettes rather than evidence to draw conclusions.
- Two VIS-linked individuals described qualitatively only; excluded from tables.
- COI: Treatments were provided at no cost to patients or the author as part of a manufacturer-sponsored demonstration event.
- Clinical examinations were performed by Dr. Wan, the operating surgeon, trained technicians, and referring ECPs. Data analysis and interpretation for this article were conducted independently by Dr. Wan.
Conclusion
Opti-K emerges as a promising, non-incisional treatment filling the space between daily optical/pharmacological therapies and permanent refractive surgery, delivering functional near vision with a favorable early safety profile.
While limited published data and the necessity of retreatment mandate rigorous patient selection and expectation management, it remains a compelling emerging technology for the hyperopic presbyope.